In More Than 140 Characters – FDA’s Social Media Guidance
Is the five-year wait over? For the U.S. pharmaceutical, biotech and medical device industry, much-desired social media guidance finally might be coming. In the webinar, “In More Than 140 Characters – FDA’s Social Media Guidance: Past, Present and Future,” FleishmanHillard’s Mark Senak reviews two recent FDA guidelines that shed some light on two primary topics: 1) the correction of misinformation on the Internet and, 2) an overview of FDA’s thinking to using social media platforms where there is limited space, such as Twitter.
Senak, author of the blog Eye on FDA, examines how the guidance could affect the industry, which up to now has had to move unevenly. The session addresses many of the topics that the new guidance has created, from the impact it has on industry communications to the areas that need further exploration by the FDA to next steps for companies.